| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Cancer Biology Program,* Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and the Urology Research Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
The majority of prostate cancers (PCa) that relapse after androgen deprivation therapy (androgen-independent PCa) continue to express androgen receptor (AR). To study the functional importance of AR in these tumors, we derived androgen-independent CWR22 PCa xenografts in castrated mice and generated a cell line from one of these xenografts (CWR22R3). Similarly to androgen-independent PCa in patients, the relapsed xenografts and cell line expressed AR and were resistant to treatment with bicalutamide. However, expression of the AR-regulated PSA gene in the CWR22R3 cell line was markedly decreased compared to the relapsed xenografts in vivo. Transfections with androgen-regulated reporter genes further indicated that the cells lacked androgen-independent AR transcriptional activity and were not hypersensitive to low androgen concentrations despite constitutive activation of the Erk/MAP kinases. Nonetheless, AR remained essential for androgen-independent growth because retroviral shRNA-mediated AR down-regulation resulted in marked long-term growth suppression. This was associated with increased levels of p27kip1 and hypophosphorylation of retinoblastoma protein but not with decreases in D-type cyclin levels or MAP kinase activation. These results reveal a potentially critical function of AR in androgen-independent PCa that is distinct from its previously described transcriptional or nontranscriptional functions.
This article has been cited by other articles:
 |
|
 |
|
  T. Vasaitis, A. Belosay, A. Schayowitz, A. Khandelwal, P. Chopra, L. K. Gediya, Z. Guo, H.-B. Fang, V. C.O. Njar, and A. M.H. Brodie Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3{beta}-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Mol. Cancer Ther., August 1, 2008; 7(8): 2348 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Ponguta, C. W. Gregory, F. S. French, and E. M. Wilson Site-specific Androgen Receptor Serine Phosphorylation Linked to Epidermal Growth Factor-dependent Growth of Castration-recurrent Prostate Cancer J. Biol. Chem., July 25, 2008; 283(30): 20989 - 21001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. N. Singh, L.-S. Wang, and S. Hannenhalli TREMOR a tool for retrieving transcriptional modules by incorporating motif covariance Nucleic Acids Res., December 18, 2007; 35(21): 7360 - 7371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Plymate, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, R. B. Montgomery, D. L. Ludwig, and J. D. Wu An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6429 - 6439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cai, C.-L. Hsieh, J. Omwancha, Z. Zheng, S.-Y. Chen, J.-L. Baert, and L. Shemshedini ETV1 Is a Novel Androgen Receptor-Regulated Gene that Mediates Prostate Cancer Cell Invasion Mol. Endocrinol., August 1, 2007; 21(8): 1835 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jiao, S. Wang, R. Qiao, I. Vivanco, P. A. Watson, C. L. Sawyers, and H. Wu Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development Cancer Res., July 1, 2007; 67(13): 6083 - 6091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, N. C. McKnight, T. Zhang, M. L. Lu, S. P. Balk, and X. Yuan SOX9 Is Expressed in Normal Prostate Basal Cells and Regulates Androgen Receptor Expression in Prostate Cancer Cells Cancer Res., January 15, 2007; 67(2): 528 - 536. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
